Preclinical activity and safety of MGD006, a CD123xCD3 Bispecific DART® molecule for the treatment of hematological malignancies

被引：3
|
作者：
Moore, P. [1 ]
Chichili, G. R. [1 ]
Huang, L. [1 ]
Li, H. [1 ]
Burke, S. [1 ]
Chen, F. [2 ]
He, L. [1 ]
Tang, Q. [1 ]
Jin, L. [1 ]
Gorlatov, S. [1 ]
Ciccarone, V. [1 ]
Koenig, S. [1 ]
Shannon, M. [1 ]
Alderson, R. [1 ]
Johnson, S. [1 ]
Bonvini, E. [1 ]
机构：
[1] MacroGenics, Rockville, MD USA
[2] MacroGenics, San Francisco, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70264-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
138
引用
收藏
页码：48 / 48
页数：1
相关论文
共 50 条
  • [41] MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
    Liu, Liqin
    Lam, Chia-Ying K.
    Long, Vatana
    Widjaja, Lusiana
    Yang, Yinhua
    Li, Hua
    Jin, Linda
    Burke, Steve
    Gorlatov, Sergey
    Brown, Jennifer
    Alderson, Ralph
    Lewis, Margaret D.
    Nordstrom, Jeffrey L.
    Koenig, Scott
    Moore, Paul A.
    Johnson, Syd
    Bonvini, Ezio
    CLINICAL CANCER RESEARCH, 2017, 23 (06) : 1506 - 1518
  • [42] EX103, a Novel CD20xCD3 Bispecific Antibody, Showed a Favorable Safety and Potent Single-Agent Antitumor Activity in Heavily Pretreated Relapsed/Refractory Patients with BCell Non-Hodgkin Lymphoma
    Qi, Junyuan
    Sun, Mingyuan
    Zhou, Keshu
    Ji, Chunyan
    Lu, Fei
    Chang, Chunkang
    Zhang, Wenjun
    Yang, Daniel
    Lu, Jiali
    Li, Jisen
    Cheng, Ying
    Li, Yanfei
    BLOOD, 2023, 142
  • [43] CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells (vol 8, e000218, 2020)
    Martens, A. W. J.
    Janssen, S. R.
    Derks, I. A. M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)
  • [44] Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor
    Geva, R.
    Vieito Villar, M.
    Ramon, J.
    Perets, R.
    Pedregal, M.
    Corral de la Fuente, E.
    Doger de Speville, B.
    Calvo, E.
    Bardina, J.
    Garralda, E.
    Brown, R. J.
    Gregor, J.
    Wu, S.
    Steinbach, D.
    Tsun-wen, S.
    Cao, Y.
    Lauring, J.
    Moreno Garcia, V.
    ANNALS OF ONCOLOGY, 2023, 34 : S633 - S634
  • [45] Efficacy and preclinical safety of ARB202, a potential first-in-class anti-CDH17/CD3 bispecific T-cell engager, for treatment of pancreatic and colorectal cancers.
    Wong, Dennis A.
    Luk, Moon Ching
    Wong, Tony K.
    Staunton, Donald E.
    Harlan, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [46] MGD011, Humanized CD19 x CD3 DART® Protein with Enhanced Pharmacokinetic Properties, Demonstrates Potent T-Cell Mediated Anti-Tumor Activity in Preclinical Models and Durable B-Cell Depletion in Cynomolgus Monkeys Following Once-a-Week Dosing
    Liu, Liqin
    Lam, Annie
    Alderson, Ralph
    Yang, Yinhua
    Li, Hua
    Long, Vatana
    Gorlatov, Sergey
    Burke, Steve
    Ciccarone, Valentina
    Nordstrom, Jeffrey
    Johnson, Syd
    Moore, Paul
    Bonvini, Ezio
    BLOOD, 2014, 124 (21)
  • [47] EX103, a re-designed CD20xCD3 bispecific antibody, showed a favorable safety and potent single-agent antitumor activity in heavily pretreated relapsed/refractory patients with B cell non-Hodgkin lymphoma
    Sun, M.
    Zhou, K.
    Ji, C.
    Lu, F.
    Chang, C.
    Zhang, W.
    Yang, D.
    Lu, J.
    Li, J.
    Cheng, Y.
    Li, Y.
    Qi, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S547 - S548
  • [48] Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).
    Lim, Emerson A.
    Schweizer, Michael Thomas
    Chi, Kim N.
    Aggarwal, Rahul Raj
    Agarwal, Neeraj
    Gulley, James L.
    Attiyeh, Edward F.
    Greger, James
    Wu, Shujian
    Jaiprasart, Pharavee
    Loffredo, John
    Bandyopadhyay, Nibedita
    Xie, Hong
    Hansen, Aaron Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [49] Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors
    Geva, Ravit
    Vieito, Maria
    Ramon, Jorge
    Perets, Ruth
    Pedregal, Manuel
    Corral, Elena
    Doger, Bernard
    Calvo, Emiliano
    Bardina, Jorge
    Garralda, Elena
    Brown, Regina J.
    Greger, James G.
    Wu, Shujian
    Steinbach, Douglas
    Yao, Tsun-Wen Sheena
    Cao, Yu
    Lauring, Josh
    Chaudhary, Ruchi
    Patel, Jaymala
    Patel, Bharvin
    Moreno, Victor
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (10)
  • [50] Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies
    Topp, Max S.
    Borchmann, Peter
    Wagner-Johnston, Nina D.
    Provencio, Mariano
    Cordoba, Raul
    Papadopoulos, Kyriakos
    Martin, Alejandro
    Grande, Carlos
    Jagadeesh, Deepa
    Lakhani, Nehal
    de Vos, Sven
    Mato, Anthony R.
    Brunnberg, Uta
    Scholl, Sebastian
    Pott, Christiane
    Rutherford, Sarah C.
    Duell, Johannes
    Adriaens, Lieve
    Ufkin, Melanie
    Kostic, Ana
    Paccaly, Anne Josee
    Gao, Bo
    Lowy, Israel
    Sternberg, David
    Carpio, Cecilia
    BLOOD, 2017, 130
12345